AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32597616 — intervention group
Group type: EXPERIMENTAL
Intervention: RI-3 (3 min rest interval)
Number of subjects: 20
Study 32597616 — intervention group
Group type: EXPERIMENTAL
Intervention: RI-1 (1 min rest interval)
Number of subjects: 20
Study 32597616 — intervention group
Group type: EXPERIMENTAL
Intervention: RI-2 (2 min rest interval)
Number of subjects: 20
Study 32597616 — intervention group
Group type: EXPERIMENTAL
Intervention: RI-1, RI-2, RI-3
Number of subjects: 20
Study 34153729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (MP) 40 mg twice daily for 7 days
Number of subjects: 76
Study 34153729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (MP) plus tocilizumab (400 mg single dose)
Number of subjects: 76
Study 34153729 — intervention group
Group type: COMPARATOR
Intervention: Usual care (historical control)
Number of subjects: 76
Study 32629706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led hypertension management model for 12 weeks
Number of subjects: 156
Study 32629706 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study 35124256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa isolates
Number of subjects: 23
Study 33566105 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized weekly coupons with nutrition education during the intervention period (A)
Number of subjects: 224
Study 33566105 — intervention group
Group type: COMPARATOR
Intervention: Occasional generic coupons with nutrition education during the control period (B)
Number of subjects: 224
Study 33566105 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized weekly coupons with nutrition education during the crossover intervention period (A)
Number of subjects: 224
Study 32461420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% CMC + 2000 IU vitamin D through buccal spray (Group B)
Number of subjects: 90
Study 32461420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% CMC + 2000 IU vitamin D through buccal spray + 0.05% cyclosporine (Group C)
Number of subjects: 90
Study 32461420 — intervention group
Group type: COMPARATOR
Intervention: 0.5% CMC (Group A)
Number of subjects: 90
Study 35297973 — intervention group
Group type: EXPERIMENTAL
Intervention: Default order for HCV screening implemented within the admission order set (hospital B during wedge 2)
Number of subjects: 7634
Study 35297973 — intervention group
Group type: COMPARATOR
Intervention: Default order for HCV screening implemented within the admission order set (hospital A during wedge 3)
Number of subjects: 7634
Study 35297973 — intervention group
Group type: COMPARATOR
Intervention: Electronic alert prompting clinicians to consider HCV screening (wedge 1)
Number of subjects: 7634
Study 36368748 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavioural therapy in a group setting (CA-CBT+)
Number of subjects: 138
Study 36368748 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 138
Study 34507009 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA)
Number of subjects: 248
Study 36355434 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 84
Study 36355434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 33337365 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0
Study 33337365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35021204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded multistranded PentaOne (Masel Orthodontics) retainer 13-23
Number of subjects: 90
Study 35021204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded multistranded PentaOne (Masel Orthodontics) retainer 12-22
Number of subjects: 90
Study 35021204 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable vacuum-formed retainer (VFR)
Number of subjects: 90
Study 35021204 — intervention group
Group type: COMPARATOR
Intervention: All three retention methods
Number of subjects: 90
Study 32076819 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 international units, intranasal application)
Number of subjects: 13
Study 32076819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 34431029 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with antidepressants for 3 weeks
Number of subjects: 70
Study 34431029 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants monotherapy for 3 weeks
Number of subjects: 70
Study 32662184 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (multicomponent community-based training program)
Number of subjects: 142
Study 34478430 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (n = 11)
Number of subjects: 20
Study 34478430 — intervention group
Group type: COMPARATOR
Intervention: E-learning (n = 9)
Number of subjects: 20
Study 33064803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep group (n=101)
Number of subjects: 136
Study 33064803 — intervention group
Group type: COMPARATOR
Intervention: Wake group (n=35)
Number of subjects: 136
Study 36331670 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg morphine sulfate ODT
Number of subjects: 104
Study 36331670 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg morphine sulfate ODT
Number of subjects: 104
Study 36331670 — intervention group
Group type: COMPARATOR
Intervention: 10 mg morphine sulfate tablet (Sevredol®)
Number of subjects: 104
Study 36331670 — intervention group
Group type: COMPARATOR
Intervention: 30 mg morphine sulfate tablet (Sevredol®)
Number of subjects: 104
Study 36331670 — intervention group
Group type: COMPARATOR
Intervention: 30 mg morphine sulfate capsule (Actiskenan®)
Number of subjects: 104
Study 36331670 — intervention group
Group type: COMPARATOR
Intervention: 30 mg morphine sulfate solution (Oramorph®)
Number of subjects: 104
Study 36331670 — intervention group
Group type: COMPARATOR
Intervention: 30 mg and 10 mg ODTs and tablets
Number of subjects: 104
Study 36331670 — intervention group
Group type: EXPERIMENTAL
Intervention: Product appreciation questionnaire
Number of subjects: 104
Study 34067585 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-prepared carbohydrate-reduced high-protein (CRHP) diet
Number of subjects: 28
Study 33066469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling Vest (VEST)
Number of subjects: 14
Study 33066469 — intervention group
Group type: COMPARATOR
Intervention: Passive Rest (PASS)
Number of subjects: 14
Study 34226073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ketamine 0.75 mg/kg
Number of subjects: 120
Study 34226073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ketamine 1 mg/kg
Number of subjects: 120
Study 34226073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ketamine 1.5 mg/kg
Number of subjects: 120
Study 33140457 — intervention group
Group type: EXPERIMENTAL
Intervention: PHY906 plus capecitabine (750 mg/m2 capecitabine b.i.d. for 14 days and 800 mg of PHY906 b.i.d. on days 1–4 and days 8–11 every 21-day cycle)
Number of subjects: 39
Study 33140457 — intervention group
Group type: EXPERIMENTAL
Intervention: PHY906 plus capecitabine
Number of subjects: 39
Study 35049373 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diquafosol ophthalmic solution, 1 drop, 6 times per day for 4 weeks
Number of subjects: 30
Study 35049373 — intervention group
Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate preservative-free artificial tears, 1 drop, 6 times per day for 4 weeks
Number of subjects: 30
Study 34431764 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Bifidobacterium longum subsp. infantis BB‐02, Bifidobacterium animalis subsp. lactis BB‐12, Streptococcus thermophilus TH‐4)
Number of subjects: 0
Study 34431764 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 0
Study 34431764 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation commenced before 5 days from birth
Number of subjects: 0
Study 35194005 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐chemo
Number of subjects: 58
Study 35194005 — intervention group
Group type: COMPARATOR
Intervention: R‐chemo
Number of subjects: 58
Study 32676739 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID original articles published in the TOP-10 journals
Number of subjects: 100
Study 32676739 — intervention group
Group type: COMPARATOR
Intervention: Opinion articles
Number of subjects: 100
Study 33909213 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling with social contextual information
Number of subjects: 0
Study 33909213 — intervention group
Group type: COMPARATOR
Intervention: Storytelling without social contextual information
Number of subjects: 0
Study 33045402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (loading dose, then 3200 IU/day)
Number of subjects: 2700
Study 33045402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2700
Study 32729244 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 154
Study 35256443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intended delivery at health facility (HF)
Number of subjects: 39679
Study 35256443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intended delivery at home
Number of subjects: 39679
Study 35256443 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 25-34 and ≥35 years delivering at home
Number of subjects: 39679
Study 35256443 — intervention group
Group type: EXPERIMENTAL
Intervention: Women delivering at HFs with primary schooling
Number of subjects: 39679
Study 35256443 — intervention group
Group type: EXPERIMENTAL
Intervention: Women delivering at HFs with more than primary education
Number of subjects: 39679
Study 35256443 — intervention group
Group type: EXPERIMENTAL
Intervention: Literate women delivering at HFs
Number of subjects: 39679
Study 35256443 — intervention group
Group type: EXPERIMENTAL
Intervention: Women not in the lowest quintile of the wealth index delivering at HFs
Number of subjects: 39679
Study 34309480 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis audio-recording intervention (4 weeks)
Number of subjects: 40
Study 34309480 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study 34400404 — intervention group
Group type: EXPERIMENTAL
Intervention: modified BLS (m-BLS)
Number of subjects: 108
Study 34400404 — intervention group
Group type: COMPARATOR
Intervention: conventional BLS (c-BLS)
Number of subjects: 108
Study 32947541 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Compression (BC)
Number of subjects: 33
Study 32947541 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF)
Number of subjects: 33
Study 34405875 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1743
Study 34405875 — intervention group
Group type: EXPERIMENTAL
Intervention: Single arterial grafting (SAG)
Number of subjects: 1743
Study 34405875 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple arterial grafting (MAG)
Number of subjects: 1743
Study 34405875 — intervention group
Group type: COMPARATOR
Intervention: Multiple arterial grafting (MAG) vs PCI
Number of subjects: 1743
Study 34405875 — intervention group
Group type: COMPARATOR
Intervention: Single arterial grafting (SAG) vs PCI
Number of subjects: 1743
Study 34405875 — intervention group
Group type: COMPARATOR
Intervention: Multiple arterial grafting (MAG) in 3VD vs PCI
Number of subjects: 1743
Study 34405875 — intervention group
Group type: COMPARATOR
Intervention: Single arterial grafting (SAG) in 3VD vs PCI
Number of subjects: 1743
Study 34405875 — intervention group
Group type: COMPARATOR
Intervention: Multiple arterial grafting (MAG) in LMCAD vs PCI
Number of subjects: 1743
Study 34405875 — intervention group
Group type: COMPARATOR
Intervention: Single arterial grafting (SAG) in LMCAD vs PCI
Number of subjects: 1743
Study 34018052 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (LC) diet
Number of subjects: 115
Study 34018052 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate (HC) diet
Number of subjects: 115
Study 33238279 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated air pollution exposure (measured using the DEHM/UBM/AirGIS model system)
Number of subjects: 33723
Study 33106180 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 33106180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 0
Study 33106180 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0
Study 33106180 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metoclopramide, ceftriaxone, and paracetamol
Number of subjects: 0
Study 33106180 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35482522 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based interventions (including cognitive behavioural therapy)
Number of subjects: 15
Study 35482522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) based interventions
Number of subjects: 15
Study 35482522 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based interventions
Number of subjects: 15
Study 33070053 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus olaparib (250 mg gefitinib daily + 200 mg olaparib three times daily)
Number of subjects: 182
Study 33070053 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib alone (250 mg daily)
Number of subjects: 182
Study 33070053 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus olaparib
Number of subjects: 182
Study 33070053 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 182
Study 35473740 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prophylactic anticoagulation (PA)
Number of subjects: 353
Study 35473740 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prophylactic anticoagulation (HD-PA)
Number of subjects: 353
Study 35473740 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation (TA)
Number of subjects: 353
Study 35473740 — intervention group
Group type: COMPARATOR
Intervention: Low-dose PA, HD-PA, or TA (combined)
Number of subjects: 353
Study 33540340 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 956
Study 34654623 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIM-DWI parameters and texture parameters of primary lesions
Number of subjects: 143
Study 34654623 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIM-DWI parameters and texture parameters of lymph nodes
Number of subjects: 143
Study 33640355 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 280
Study 33640355 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 280
Study 34286397 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids capsule along with standard care
Number of subjects: 60
Study 34286397 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (control group)
Number of subjects: 60
Study 34909899 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic transsphenoidal pituitary surgery
Number of subjects: 46
Study 34909899 — intervention group
Group type: COMPARATOR
Intervention: Microscopic transseptal pituitary surgery
Number of subjects: 46
Study 34255034 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg cholecalciferol daily for 12 weeks (with UVB exposure)
Number of subjects: 100
Study 34255034 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg cholecalciferol daily for 12 weeks (without UVB exposure)
Number of subjects: 100
Study 34255034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with UVB exposure)
Number of subjects: 100
Study 34255034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without UVB exposure)
Number of subjects: 100
Study 34255034 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg cholecalciferol (both groups)
Number of subjects: 100
Study 34255034 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg cholecalciferol
Number of subjects: 100
Study 33259542 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 9198
Study 33259542 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (age-matched women without hysterectomy)
Number of subjects: 9198
Study 35760910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg daily
Number of subjects: 97
Study 35760910 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg daily
Number of subjects: 97
Study 35760910 — intervention group
Group type: COMPARATOR
Intervention: Control group (hydration only)
Number of subjects: 97
Study 34465955 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine intrarectal disinfection
Number of subjects: 621
Study 34465955 — intervention group
Group type: COMPARATOR
Intervention: Formalin needle disinfection
Number of subjects: 621
Study 36215853 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced ambulatory care competencies through didactic content and clinical experiences
Number of subjects: 0
Study 36215853 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations as part of the training
Number of subjects: 0
Study 34297067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (1000 IU/d)
Number of subjects: 372
Study 34297067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 34297067 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 372
Study 32056816 — intervention group
Group type: EXPERIMENTAL
Intervention: IC with modified contract‐relax proprioceptive neuromuscular facilitation (PNF) stretching
Number of subjects: 40
Study 32056816 — intervention group
Group type: EXPERIMENTAL
Intervention: IC with myofascial release
Number of subjects: 40
Study 32056816 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 40
Study 32056816 — intervention group
Group type: EXPERIMENTAL
Intervention: IC with static stretching
Number of subjects: 40
Study 34791262 — intervention group
Group type: EXPERIMENTAL
Intervention: Seltorexant 20 mg
Number of subjects: 0
Study 34791262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33397313 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved baking stove intervention
Number of subjects: 5508
Study 33397313 — intervention group
Group type: COMPARATOR
Intervention: Continuation of open burning traditional baking stove
Number of subjects: 5508
Study 35704592 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal chart
Number of subjects: 0
Study 35704592 — intervention group
Group type: COMPARATOR
Intervention: Misleading chart
Number of subjects: 0
Study 34161143 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 29
Study 34161143 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 29
Study 34161143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 33844367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention organs
Number of subjects: 249
Study 33844367 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk to the kidney from the intervention
Number of subjects: 249
Study 33844367 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger donor age
Number of subjects: 249
Study 33844367 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer time until the next organ offer
Number of subjects: 249
Study 33844367 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater trust in their transplant physician
Number of subjects: 249
Study 33844367 — intervention group
Group type: EXPERIMENTAL
Intervention: Waitlisted longer
Number of subjects: 249
Study 33844367 — intervention group
Group type: EXPERIMENTAL
Intervention: Being Black
Number of subjects: 249
Study 32662209 — intervention group
Group type: EXPERIMENTAL
Intervention: Boric acid impregnated sponge combined with NPWT system
Number of subjects: 100
Study 32662209 — intervention group
Group type: COMPARATOR
Intervention: Silver nitrate sponge
Number of subjects: 100
Study 35055339 — intervention group
Group type: EXPERIMENTAL
Intervention: Farmalarm app (experimental group)
Number of subjects: 150
Study 35055339 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up (control group)
Number of subjects: 150
Study 33059607 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-diphtheria toxoid typhoid conjugate vaccine (Vi-DT)
Number of subjects: 200
Study 33059607 — intervention group
Group type: COMPARATOR
Intervention: Vi-polysaccharide vaccine (Vi-PS)
Number of subjects: 200
Study 33059607 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-DT
Number of subjects: 200
Study 33059607 — intervention group
Group type: COMPARATOR
Intervention: Vi-PS
Number of subjects: 200
Study 33559711 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT-based CNN models
Number of subjects: 197
Study 33559711 — intervention group
Group type: COMPARATOR
Intervention: CT-based CNN models
Number of subjects: 197
Study 33559711 — intervention group
Group type: COMPARATOR
Intervention: PET-based CNN models
Number of subjects: 197
Study 33559711 — intervention group
Group type: COMPARATOR
Intervention: Manual assessment by oncologist
Number of subjects: 197
Study 36443713 — intervention group
Group type: EXPERIMENTAL
Intervention: 82Rb PET/CT after amino acid-infusion
Number of subjects: 17
Study 36443713 — intervention group
Group type: COMPARATOR
Intervention: 82Rb PET/CT before amino acid-infusion (baseline)
Number of subjects: 17
Study 36443713 — intervention group
Group type: EXPERIMENTAL
Intervention: 82Rb PET/CT scans on Day A and Day B
Number of subjects: 17
Study 34404427 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz taVNS
Number of subjects: 24
Study 34404427 — intervention group
Group type: COMPARATOR
Intervention: Pre-taVNS resting state
Number of subjects: 24
Study 34404427 — intervention group
Group type: COMPARATOR
Intervention: 20 Hz taVNS
Number of subjects: 24
Study 34171556 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling sessions based on emotional stories
Number of subjects: 35
Study 34171556 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling sessions based on referential stories
Number of subjects: 35
Study 36117055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treprostinil (TRE)
Number of subjects: 690
Study 36117055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690